ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR

中文名称:

ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR

中文同义词:

GLUCAGON (19-29) (人)

英文名称:

H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH

英文同义词:

AQDFVQWLMNT;H-ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR-OH;GLUCAGON (19-29), BOVINE, HUMAN, PORCINE;GLUCAGON (19-29), HUMAN;GLUCAGON (19-29) (HUMAN, BOVINE, PORCINE);ALA-GLN-ASP-PHE-VAL-GLN-TRP-LEU-MET-ASN-THR;glucagon(19-29;PHE-VAL-GLN-TRP-LEU-MET-ASN-THR: FVQWLMNT

CAS号:

64790-15-4

分子式:

C61H89N15O18S

分子量:

1352.51

EINECS号:

相关类别:

多肽;Peptide;Obesity

Mol文件:

64790-15-4.mol

沸点 

1828.5±65.0 °C(Predicted)

密度 

1.339±0.06 g/cm3(Predicted)

储存条件 

-15°C

酸度系数(pKa)

3.19±0.10(Predicted)

生物活性

Glucagon (19-29), human是高效的胰岛素分泌抑制剂。

靶点

Insulin secretion

体外研究

Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29).

体内研究

Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca 2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein.